|
KMID : 0923620230230060043
|
|
Immune Network
2023 Volume.23 No. 6 p.43 ~ p.43
|
|
|
Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine
|
|
Eliel Nham
Kim Jin-Eui
Lee Jung-Min
Park Hee-Do
Kim Jeong-Hun
Lee So-Hyun
Choi Jae-Uk
Kim Kyung-Taek
Yoon Jin-Gu
Hwang Soon-Young
Song Joon-Young
Cheong Hee-Jin
Kim Woo-Joo
Park Man-Seong
Noh Ji-Yun
|
|
|
Abstract
|
|
|
|
The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has provided insights for updating current coronavirus disease 2019 (COVID-19) vaccines. We examined the neutralizing activity of Abs induced by a BA.4/5-containing bivalent mRNA vaccine against Omicron subvariants BN.1 and XBB.1.5. We recruited 40 individuals who had received a monovalent COVID-19 booster dose after a primary series of COVID-19 vaccinations and will be vaccinated with a BA.4/5-containing bivalent vaccine. Sera were collected before vaccination, one month after, and three months after a bivalent booster. Neutralizing Ab (nAb) titers were measured against ancestral SARS-CoV-2 and Omicron subvariants BA.5, BN.1, and XBB.1.5. BA.4/5-containing bivalent vaccination significantly boosted nAb levels against both ancestral SARS-CoV-2 and Omicron subvariants. Participants with a history of SARS-CoV-2 infection had higher nAb titers against all examined strains than the infection-naive group. NAb titers against BN.1 and XBB.1.5 were lower than those against the ancestral SARS-CoV-2 and BA.5 strains. These results suggest that COVID-19 vaccinations specifically targeting emerging Omicron subvariants, such as XBB.1.5, may be required to ensure better protection against SARS-CoV-2 infection, especially in high-risk groups.
|
|
|
KEYWORD
|
|
|
Antibodies, neutralizing, COVID-19, SARS-CoV-2, Vaccine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|